Using Poly(amidoamine) PAMAM-βCD Dendrimer for Controlled and Prolonged Delivery of Doxorubicin as Alternative System for Cancer Treatment
Pharmaceutics · 23.11.2024 · 16 (12) · 1509
DOI: 10.3390/pharmaceutics16121509 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 23.11.2024. Verfasst von Kendra Sorroza-Martínez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Sistemas Biológicos, Unidad Xochimilco, Universidad Autónoma Metropolitana, Calzada del Hueso 1100, Col. Villa Quietud, Mexico City C…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CONAHCYT, PAPIIT-DGAPA.
Abstract (Originalsprache)
Background/Objectives: Doxorubicin (Dox) is an anticancer drug used in the treatment of a wide range of solid tumors; however, Dox causes systemic toxicity and irreversible cardiotoxicity. The design of a new nanosystem that allows for the control of Dox loading and delivery results is a powerful tool to control Dox release only in cancer cells. For this reason, supramolecular self-assembly was performed between a poly(amidoamine) (PAMAM) dendrimer decorated with four β-cyclodextrin (βCD) units (PAMAM-βCD) and an adamantane–hydrazone–doxorubicin (Ad-h-Dox) prodrug.
Methods
The formation of inclusion complexes (ICs) between the prodrug and all the βCD cavities present on the surface of the PAMAM-βCD dendrimer was followed by 1H-NMR titration and corroborated by 2D NOESY experiments. A full characterization of the supramolecular assembly was performed in the solid state by thermal analysis (DSC/TGA) and scanning electron microscopy (SEM) and in solution by the DOSY NMR technique in D2O. Furthermore, the Dox release profiles from the PAMAM-βCD/Ad-h-Dox assembly at different pH values was studied by comparing the efficiency against a native βCD/Ad-h-Dox IC. Additionally, in vitro cytotoxic activity assays were performed for the nanocarrier alone and the two supramolecular assemblies in different carcinogenic cell lines.
Results
The PAMAM-βCD/Ad-h-Dox assembly was adequately characterized, and the cytotoxic activity results demonstrate that the nanocarrier alone and its hydrolysis product are innocuous compared to the PAMAM-βCD/Ad-h-Dox nanocarrier that showed cytotoxicity equivalent to free Dox in the tested cancer cell lines. The in vitro drug release assays for the PAMAM-βCD/Ad-h-Dox system showed an acidic pH-dependent behavior and a prolonged profile of up to more than 72 h.
Conclusions
The design of PAMAM-βCD/Ad-h-Dox consists of a new controlled and prolonged Dox release system for potential use in cancer treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departamento de Sistemas Biológicos, Unidad Xochimilco, Universidad Autónoma Metropolitana, Calzada del Hueso 1100, Col. Villa Quietud, Mexico City CP 04960, Mexico.
- Departamento de Biología, Facultad de Química, Universidad Nacional Autónoma de México, Circuito Escolar, Ciudad Universitaria, Mexico City CP 04510, Mexico.
- Centro de Investigaciones Químicas, Instituto de Investigación en Ciencias Básicas y Aplicadas, Universidad Autónoma del Estado de Morelos, Av. Universidad 1001, Col. Chamilpa, Cuernavaca CP 62209, Mexico.
- Departamento de Biología Celular y Tisular, Facultad de Medicina, Universidad Nacional Autónoma de México, Circuito Escolar, Ciudad Universitaria, Mexico City CP 04510, Mexico.
- Departamento de Reología, Instituto de Investigaciones en Materiales, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Mexico City CP 04510, Mexico.
ORCID-Profile: Ignacio González-Sánchez, Raúl Villamil-Ramos, Israel González-Méndez
Förderung
- CONAHCYT
- PAPIIT-DGAPA
Zitieren
APA
Sorroza-Martínez, K., González-Sánchez, I., Villamil-Ramos, R., Cerbón, M., Guerrero-Álvarez, J. A., Coronel-Cruz, C., Rivera, E., & González-Méndez, I. (2024). Using Poly(amidoamine) PAMAM-βCD Dendrimer for Controlled and Prolonged Delivery of Doxorubicin as Alternative System for Cancer Treatment. Pharmaceutics, 16(12), 1509. https://doi.org/10.3390/pharmaceutics16121509
Vancouver
Sorroza-Martínez K, González-Sánchez I, Villamil-Ramos R, Cerbón M, Guerrero-Álvarez JA, Coronel-Cruz C, et al. Using Poly(amidoamine) PAMAM-βCD Dendrimer for Controlled and Prolonged Delivery of Doxorubicin as Alternative System for Cancer Treatment. Pharmaceutics. 2024;16(12):1509. doi:10.3390/pharmaceutics16121509
BibTeX
@article{SorrozaMartnez2024,
author = {Sorroza-Martínez, Kendra and González-Sánchez, Ignacio and Villamil-Ramos, Raúl and Cerbón, Marco and Guerrero-Álvarez, Jorge Antonio and Coronel-Cruz, Cristina and Rivera, Ernesto and González-Méndez, Israel},
title = {Using Poly(amidoamine) PAMAM-βCD Dendrimer for Controlled and Prolonged Delivery of Doxorubicin as Alternative System for Cancer Treatment},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {12},
pages = {1509},
doi = {10.3390/pharmaceutics16121509}
}
EUVIMED